Endometrial metastasis from breast cancer in a patient receiving tamoxifen therapy
Endometrial metastasis from breast cancer in a patient receiving tamoxifen therapy
复制标题
DOI：
10.1159/000010299
复制
发表时间：
2000-01-01
影响因子：
2.1
通讯作者：
Baier, D
中科院分区：
文献类型：
--
作者：
Horn, LC;Einenkel, J;Baier, D
已知他莫昔芬（TAM）与几种类型的子宫内膜病理学有关，例如，增生、息肉和子宫内膜癌，有时是特殊的组织学类型。在这里，我们报告了一个罕见的情况下，子宫内膜转移的乳腺癌（导管癌）发现在TAM治疗。这种情况并不表明TAM治疗会导致乳腺癌的子宫内膜转移。然而，临床医生应该意识到这种可能性，并为接受TAM治疗的患者提供密切的妇科随访，使用自由的子宫内膜活检指征。版权所有（C）2000 S. Karger AG，巴塞尔。
Tamoxifen (TAM) is known to be associated with several types of endometrial pathologies, e,g, hyperplasias, polyps and endometrial carcinomas, sometimes of special histologic type. Here we report a rare case of endometrial metastasis from a breast carcinoma (ductal carcinoma) discovered during TAM therapy. This occurrence does not suggest that TAM treatment causes endometrial metastases of breast cancer. However, clinicians should be aware of this possibility and provide patients receiving TAM therapy with close gynecologic follow-up using liberal indications for endometrial biopsies. Copyright (C) 2000 S. Karger AG, Basel.